Loading...
01/10 16:01
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call presents a mixed picture. Financial performance shows reduced losses and expenses, which is positive, but cash reserves are dwindling. Product development updates and strategic plans seem promising, but are contingent on future FDA approvals and trial outcomes, posing significant risks. The Q&A session reveals potential market opportunities but lacks clarity on pricing strategies and timelines. Overall, the sentiment is neutral, as the positive aspects are balanced by uncertainties and risks, particularly in regulatory and market adoption areas.
Cash, cash equivalents, and short-term investments $13.9 million as of September 30, 2025, compared to $44.9 million as of December 31, 2024. The decrease is due to operational expenses, but this excludes net proceeds of approximately $94 million from a $100 million underwritten offering closed on November 5, 2025.
Cash used in operations $6.7 million for Q3 2025 compared to $16.7 million for Q3 2024, a decrease of $10 million. The reduction is attributed to lower operational costs.
Research and development expense $4 million for Q3 2025 compared to $11.1 million for Q3 2024, a decrease of $7.1 million. The decrease is primarily due to the wind-down of clinical trials for REL-1017, partially offset by increased costs for NDV-01 and sepranolone studies and an increase in R&D employees.
General and administrative expense $6.3 million for Q3 2025 compared to $11.9 million for Q3 2024, a decrease of $5.6 million. The decrease is primarily driven by reduced stock-based compensation and lower direct employee and administrative expenses.
Net loss $10.1 million for Q3 2025 compared to $21.7 million for Q3 2024, a decrease of $11.6 million. The reduction is due to lower R&D and administrative expenses.
NDV-01 development: Reported 9-month follow-up data from Phase II study in NMIBC patients, showing a 92% overall response rate at any time with favorable safety. Secured FDA alignment on Phase III program, enabling two distinct registrational tracks. Phase III studies to begin in the first half of 2026.
Sepranolone development: Selected for Prader-Willi Syndrome (PWS) as the first clinical indication. Phase II study in PWS to start in the first half of 2026. Focused on normalizing GABA-A receptor activity to address compulsive disorders.
Market opportunity for NDV-01: Targets NMIBC, affecting 68,000 new patients annually in the U.S. and a prevalence of 744,000 patients. Potential to address high-risk and intermediate-risk NMIBC cases.
Financial position: Completed $100 million underwritten financing, providing resources to support operations into 2028. Cash, cash equivalents, and short-term investments at $13.9 million as of September 30, 2025, excluding recent financing proceeds.
Operational efficiencies: Reduced R&D expenses by $7.1 million and G&A expenses by $5.6 million in Q3 2025 compared to Q3 2024, driven by lower study costs and administrative expenses.
Strategic hires and advisory board: Appointed Dr. Raj Pruthi as Chief Medical Officer, Uro-oncology, and established a Clinical Advisory Board for NDV-01, including prominent leaders in NMIBC.
Regulatory Risks: The company is heavily reliant on FDA approvals for its NDV-01 and sepranolone programs. Any delays or negative outcomes in regulatory discussions or approvals could significantly impact the company's ability to bring these therapies to market.
Clinical Development Risks: The success of NDV-01 and sepranolone depends on the outcomes of ongoing and future clinical trials. Any unfavorable results, such as safety concerns or lack of efficacy, could derail the programs.
Financial Risks: Although the company has secured funding to support operations into 2028, it remains dependent on external financing for long-term sustainability. Any challenges in raising additional funds could impact its ability to execute strategic plans.
Manufacturing and Supply Chain Risks: The company is in the process of transferring production to contract manufacturers for NDV-01 and sepranolone. Any delays or issues in scaling up production could affect the timelines for clinical trials and eventual commercialization.
Market Adoption Risks: Even if approved, the therapies face competitive pressures and challenges in achieving broad clinical adoption, particularly in the crowded oncology and compulsive disorder treatment markets.
NDV-01 Phase III Program: Relmada plans to initiate two separate registrational studies for NDV-01 in non-muscle invasive bladder cancer (NMIBC) in the first half of 2026. The FDA has aligned on two distinct registrational paths: one for high-risk second-line BCG unresponsive NMIBC patients and another for intermediate-risk NMIBC in the adjuvant setting. The company aims to complete study design and initiate the program in early 2026.
Sepranolone Phase II Study: Relmada intends to initiate a Phase II proof-of-concept study for sepranolone in Prader-Willi Syndrome (PWS) in the first half of 2026. Preparations include engaging with the FDA on trial design and establishing a supply chain.
Financial Outlook: The company is well-capitalized following a $100 million underwritten financing, with resources to support planned operations into 2028. This includes funding for the NDV-01 registration studies and the sepranolone Phase II study.
NDV-01 Manufacturing and Supply Chain: Efforts are underway to transfer production to contract manufacturers, complete scale-up, and produce clinical batches for the NDV-01 program.
The selected topic was not discussed during the call.
The earnings call presents a mixed picture. Financial performance shows reduced losses and expenses, which is positive, but cash reserves are dwindling. Product development updates and strategic plans seem promising, but are contingent on future FDA approvals and trial outcomes, posing significant risks. The Q&A session reveals potential market opportunities but lacks clarity on pricing strategies and timelines. Overall, the sentiment is neutral, as the positive aspects are balanced by uncertainties and risks, particularly in regulatory and market adoption areas.
Despite promising product developments and reduced losses, Relmada's high cash burn rate, decreased cash reserves, and looming financial sustainability issues pose significant risks. The Q&A highlights uncertainties in regulatory pathways and market strategies, with potential delays in trials and increased competition. The company's financial situation is precarious, with limited cash to support future R&D activities. Without a clear path to additional financing or significant revenue, the stock is likely to experience negative sentiment, especially in the absence of a market cap to buffer volatility.
The earnings call reveals several concerns: an EPS miss, increased cash burn, and reduced cash reserves, suggesting financial instability. Regulatory and competitive risks further exacerbate uncertainties. Despite some optimism in product development, unclear management responses in the Q&A and the lack of guidance add to the negative sentiment. The net loss improvement is overshadowed by operational challenges and financial concerns, leading to a predicted stock movement of -2% to -8%.
The earnings call reveals financial challenges, including a shrinking cash balance and increased cash used in operations, raising liquidity concerns. Despite some positive indicators like reduced net loss and promising initial data for NDV-01, the lack of clear guidance and potential regulatory and operational risks overshadow the positives. The management's vague responses in the Q&A add to the uncertainty. Given these factors, a negative sentiment is warranted, suggesting a potential stock price decline of 2% to 8% over the next two weeks.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
